CSL Reports Five-Year Efficacy of HEMGENIX, Benefiting 75 Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 07 2025
0mins
Source: PRnewswire
- Durable Efficacy: The HOPE-B study shows that 94% of patients remained free from continuous prophylaxis treatment five years after a single infusion of HEMGENIX, demonstrating the therapy's long-term efficacy and safety.
- Stable Factor Activity: At five years, mean factor IX activity levels were maintained at 36.1%, not only confirming HEMGENIX's effectiveness but also enhancing patients' quality of life by reducing bleeding episodes.
- Global Adoption: More than 75 individuals across eight countries have received HEMGENIX, reflecting its growing acceptance and recognition worldwide, which is likely to drive market demand further.
- Future Monitoring Plans: Although the five-year data from the HOPE-B study is complete, participants will continue to be monitored in the IX-TEND 222-3003 study, ensuring the accumulation of long-term efficacy and safety data.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CSL with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CSL
Wall Street analysts forecast CSL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSL is 385.33 USD with a low forecast of 356.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 341.010
Low
356.00
Averages
385.33
High
400.00
Current: 341.010
Low
356.00
Averages
385.33
High
400.00
About CSL
Carlisle Companies Incorporated is a manufacturer and supplier of building envelope products and solutions that enable energy efficiency in buildings. Its segments include Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The CCM segment produces a complete line of energy-efficient single-ply roofing products and warranted roof systems and accessories for the commercial building industry, including ethylene propylene diene monomer (EPDM), thermoplastic polyolefin (TPO) and polyvinyl chloride (PVC) membrane, polyisocyanurate (polyiso) insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. CWT segment produces building envelope solutions that drive energy efficiency and sustainability in commercial and residential applications. Its products include waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid and sheet applied air/vapor barriers and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Carlisle Companies Sets Vision 2030 with 5% Organic Growth Target
- Strategic Vision: Carlisle Companies' Vision 2030 aims to enhance efficiency through its internal operating system, targeting a 5% organic revenue growth that will further solidify its position in the building materials market.
- Financial Goals: The company plans to maintain free cash flow margins above 15% and adjusted EBITDA margins at 25% or more, with a target of achieving a 25% return on invested capital, potentially leading to $40 in adjusted earnings per share by 2030.
- Innovation-Driven Growth: Carlisle intends to boost R&D spending to ensure that new products contribute 25% of total revenue by 2030, while advanced automation technology is expected to reduce costs by 1% to 2% of revenue annually, enhancing overall operational efficiency.
- Acquisition Strategy: Recent acquisitions of metal systems specialist MTL, insulation provider Plasti-Fab, and recycled denim insulation pioneer Bonded Logic are anticipated to yield significant synergy-related cost savings and open new markets, supporting the company's Vision 2030 objectives.
Continue Reading
Carlisle's Vision 2030 Strategy Targets 5% Annual Revenue Growth
- Strategic Vision: Carlisle's Vision 2030 aims for 5% organic revenue growth, maintaining free cash flow margins above 15%, and adjusted EBITDA margins of over 25%, potentially delivering substantial returns for shareholders.
- Cost Control: The company plans to enhance efficiency by leveraging advanced automation and technology to cut annual costs by 1% to 2% of revenue, significantly improving operational performance and competitive positioning.
- R&D Investment: Carlisle intends to increase R&D spending to 25% of total revenue by 2030, driving new product development to expand market share and meet evolving customer demands.
- Acquisition Integration: Recent acquisitions of metal systems specialist MTL, insulation provider Plasti-Fab, and recycled denim insulation pioneer Bonded Logic are expected to generate significant synergies and cost savings, supporting the achievement of the Vision 2030 goals.
Continue Reading